Genentech Inc, A Member of the Roche Group, South San Francisco, CA, USA.
Clin Ther. 2018 Dec;40(12):1967-1972. doi: 10.1016/j.clinthera.2018.09.016. Epub 2018 Oct 26.
In recent decades, the field of drug safety/pharmacovigilance (PV) has advanced dramatically in some ways and yet has remained stagnant or progressed slowly in others. One way to assess the PV landscape is to view it through both a regulatory lens and a science and technology lens. This commentary highlights some of the current PV issues that can be resolved by sustained collaboration among all relevant stakeholders.
近几十年来，药物安全/药物警戒（PV）领域在某些方面取得了显著进展，但在其他方面却停滞不前或进展缓慢。评估 PV 现状的一种方法是同时从监管和科学技术的角度来看待它。本评论强调了一些当前的 PV 问题，可以通过所有相关利益相关者之间的持续合作来解决。
